Cargando…

Evolution of meningococcal carriage in serogroups X and Y before introduction of MenAfriVac in the health district of Kaya, Burkina Faso

BACKGROUND: The objective of this study was to evaluate the carriage of Neisseria meningitidis (Nm) serogroups X and Y in the health district of Kaya before the introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso. METHODS: A repeated cross-sectional meningococcal carriage s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ba, Absatou Ky, Sanou, Idrissa, Kristiansen, Paul A, Sangaré, Lassana, Ouédraogo, Rasmata, Ouattara, Kalifa, Kienou, Maxime, Tiendrebeogo, Simon, Tranchot, Juliette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201702/ https://www.ncbi.nlm.nih.gov/pubmed/25311771 http://dx.doi.org/10.1186/s12879-014-0546-8

Ejemplares similares

Persistent low carriage of serogroup A Neisseria meningitidistwo years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac
por: Kristiansen, Paul A, et al.
Publicado: (2014)

MenAfriVac as an Antitetanus Vaccine
por: Borrow, Ray, et al.
Publicado: (2015)

Bacterial meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign
por: Diallo, Alpha Oumar, et al.
Publicado: (2017)

Introduction of Preventive Vaccination of Meningococcal Meningitis using MenAfriVac in Northern Uganda 2017
por: Ssewankambo, Fred
Publicado: (2017)

Prevalence and epidemiology of meningococcal carriage in Southern Ethiopia prior to implementation of MenAfriVac, a conjugate vaccine
por: Bårnes, Guro K., et al.
Publicado: (2016)

Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine
por: Kristiansen, Paul A, et al.
Publicado: (2013)

Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac
por: Tang, Yuxiao, et al.
Publicado: (2015)

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt
por: Karachaliou, Andromachi, et al.
Publicado: (2015)

Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac(®) in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa
por: Viviani, Simonetta
Publicado: (2022)

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials
por: Idoko, Olubukola T., et al.
Publicado: (2015)

Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali
por: Roy Chowdhury, Panchali, et al.
Publicado: (2015)

Understanding the Role of Duration of Vaccine Protection with MenAfriVac: Simulating Alternative Vaccination Strategies
por: Karachaliou Prasinou, Andromachi, et al.
Publicado: (2021)

Meningococcal carriage 7 years after introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso: results from four cross-sectional carriage surveys
por: Mbaeyi, Sarah, et al.
Publicado: (2020)

Molecular insights into meningococcal carriage isolates from Burkina Faso 7 years after introduction of a serogroup A meningococcal conjugate vaccine
por: Topaz, Nadav, et al.
Publicado: (2020)

Impact of MenAfriVac on Meningococcal A Meningitis in Cameroon: A Retrospective Study Using Case-by-Case-Based Surveillance Data from 2009 to 2015
por: Gake, Bouba, et al.
Publicado: (2021)

A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians
por: Tapia, Milagritos D., et al.
Publicado: (2015)

Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age
por: Tapia, Milagritos D., et al.
Publicado: (2015)

Knowledge, beliefs and practices regarding prevention of bacterial meningitis in Burkina Faso, 5 years after MenAfriVac mass campaigns
por: Mueller, Judith E., et al.
Publicado: (2021)

A field based evaluation of adverse events following MenAfriVac(®)vaccine delivered in a controlled temperature chain (CTC) approach in Benin
por: Steffen, Christoph, et al.
Publicado: (2014)

Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years
por: Diallo, Aldiouma, et al.
Publicado: (2015)

Molecular characterization of invasive meningococcal isolates in Burkina Faso as the relative importance of serogroups X and W increases, 2008–2012
por: Retchless, Adam C., et al.
Publicado: (2018)

Caractérisation de la flore bactérienne des péritonites communautaires opérées au Burkina Faso
por: Sanou, Mahamoudou, et al.
Publicado: (2014)

L’utilisation de l’approche CTC: quel impact sur la couverture vaccinale lors de la campagne préventive de vaccination contre la méningite A avec le MenAfriVac au Togo en 2014?
por: Landoh, Dadja Essoya, et al.
Publicado: (2017)

The Establishment and Diversification of Epidemic-Associated Serogroup W Meningococcus in the African Meningitis Belt, 1994 to 2012
por: Retchless, Adam C., et al.
Publicado: (2016)

Meningococcal disease serogroup C
por: Dickinson, Félix O, et al.
Publicado: (2012)

Identification of Streptococcus suis Meningitis by Direct Triplex Real-Time PCR, Burkina Faso
por: Ouattara, Mahamoudou, et al.
Publicado: (2020)

Molecular Characterization of Invasive Meningococcal Isolates from Countries in the African Meningitis Belt before Introduction of a Serogroup A Conjugate Vaccine
por: Caugant, Dominique A., et al.
Publicado: (2012)

Why oral antiseptic mouth rinsing before sputum collection cannot reduce contamination rate of mycobacterial culture in Burkina-Faso
por: Kabore, Antoinette, et al.
Publicado: (2019)

Serogroup Y Meningococcal Disease, Colombia
por: Agudelo, Clara Inés, et al.
Publicado: (2008)

The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology
por: Racloz, Vanessa N, et al.
Publicado: (2010)

Milieu sélectif de Lowenstein-Jensen à base de vancomycine pour la réduction des contaminations de cultures de mycobactéries par les bactéries sporulantes
por: Gomgnimbou, Michel Kiréopori, et al.
Publicado: (2020)

Serogroup X in Meningococcal Disease, Western Kenya
por: Materu, Sadiki, et al.
Publicado: (2007)

Toward an Improved Meningococcal Serogroup B Assay
por: Poolman, Jan
Publicado: (2018)

Nationwide Trends in Bacterial Meningitis before the Introduction of 13-Valent Pneumococcal Conjugate Vaccine—Burkina Faso, 2011–2013
por: Kambiré, Dinanibè, et al.
Publicado: (2016)

Characterization of virulence factors of Salmonella isolated from human stools and street food in urban areas of Burkina Faso
por: Nikiema, Marguerite E. M., et al.
Publicado: (2021)

Whatman FTA cards versus plasma specimens for the quantitation of HIV-1 RNA using two real-time PCR assays
por: Yacouba, Abdourahamane, et al.
Publicado: (2020)

Neisseria meningitidis Serogroup W, Burkina Faso, 2012
por: MacNeil, Jessica R., et al.
Publicado: (2014)

Serogroup W135 Meningococcal Disease, The Gambia, 2012
por: Hossain, M. Jahangir, et al.
Publicado: (2013)

An Unexpected Fever Post Serogroup B Meningococcal Sepsis
por: Donà, Daniele, et al.
Publicado: (2016)

Meningococcal serogroups and surveillance: a systematic review and survey
por: Peterson, Meagan E, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8k104klae2t0567er8k6rbn4dq